Osteoarthritis Injection Cost in India: What Drives It

This covers what determines osteoarthritis injection cost across the three main intra-articular options, what the evidence actually supports for each, what government schemes cover and don't, and why the cost conversation looks different at a hospital pharmacy than it does for a single outpatient visit.

What are the three main types of osteoarthritis injections?

Corticosteroid injections use a generic anti-inflammatory drug in clinical use for decades. It carries the lowest per-injection drug cost of the three categories. Intra-articular hyaluronic acid, known clinically as viscosupplementation, replaces synovial fluid viscosity. It is regulated and priced as a device or biological product rather than a small-molecule generic drug, which keeps its unit cost structurally higher.

Platelet-rich plasma is prepared from the patient's own blood at the point of care, so its cost is driven almost entirely by the processing kit, centrifuge time and clinician time rather than by any manufactured drug price. An Indian expert consensus report involving 78 orthopaedic surgeons noted that the absence of standard national guidance on hyaluronic acid use had produced wide variation in how and when it gets prescribed, which itself affects how consistently it gets budgeted for.

Does the evidence support paying more for one injection type over another?

A systematic review of injection-based osteoarthritis knee guidelines found that recommendations differ meaningfully between clinical societies. Some endorse hyaluronic acid for mild-to-moderate disease; others find the evidence too inconsistent to recommend routinely. This split matters directly for cost. A hospital paying a premium for an agent some guideline bodies decline to endorse is making a genuinely contested clinical bet, not a settled one.

A comprehensive narrative review of platelet-rich plasma evidence found leukocyte-poor PRP preparations showing superior pain relief compared with hyaluronic acid and corticosteroids in some trials, particularly for mild-to-moderate disease, while other high-quality placebo-controlled trials failed to show benefit beyond six to twelve months. The clinical picture, in short, does not currently support treating any one injection type as categorically worth its added cost over the others for every patient.

What does the government actually cover for osteoarthritis treatment?

Ayushman Bharat's Health Benefit Package, the master list under which Pradhan Mantri Jan Arogya Yojana reimburses hospitals, was revised with package rates raised by 20% to 400% across procedures in its most recent update. The packages are built around surgical end-stage procedures such as total knee replacement, not individual outpatient injections.

A single viscosupplementation or PRP injection administered in an outpatient department is generally not a distinct PM-JAY package the way surgery is.

This creates a real gap: government scheme coverage concentrates at the point a patient has already progressed to needing surgery, while the injection-based interventions that might delay that point sit largely outside package reimbursement and fall to out-of-pocket payment or private insurance instead. A hospital orthopaedics department planning its osteoarthritis service line needs to budget injection costs and surgical costs on two entirely different reimbursement logics.

State government health schemes and employee health schemes sometimes fill part of this gap with their own outpatient package rates, but coverage is inconsistent state to state and rarely publicised as clearly as PM-JAY's national package list. A patient asking a hospital billing desk whether an injection is "covered" is often asking a question the desk cannot answer with a single yes or no.

Why does the same injection cost differently at different hospitals?

Procurement volume explains most of the variation a patient sees between institutions offering the identical injectable product. A hospital buying hyaluronic acid or PRP kits in bulk for a busy joint clinic negotiates a materially different per-unit cost than a smaller nursing home ordering single units reactively.

Corticosteroids are older, more commoditised generic drugs. They show far less price spread between institutions than hyaluronic acid or PRP kits do, since generic competition has already compressed most of the margin out of that category. The newer, less commoditised categories are exactly where a hospital's own purchasing discipline decides whether the injection is a marginal loss-leader or a sustainable service line.

A third factor rarely discussed openly: consumables and disposal. PRP processing kits, centrifuge tubes and sharps disposal add a real per-procedure cost on top of the blood draw itself, one that varies by which kit brand a hospital has standardised on and how many procedures it runs per week.

What should a hospital or clinic actually budget for an osteoarthritis injection service?

A joint-injection service line needs separate stocking logic for each category rather than one blended "injectables" budget line. Corticosteroids move on standard pharmacy reorder cycles like any other generic anti-inflammatory. Hyaluronic acid and PRP kits need forward booking against a scheduled patient list, since both carry shelf-life and cold-chain considerations that make speculative overstocking expensive if a booked patient cancels.

Our managed hospital pharmacy services guide covers how a hospital keeps injectable and device-classified stock like hyaluronic acid reliably available in-house instead of sending patients to an outside supplier mid-treatment, and our prescription leakage piece covers what happens to a hospital's own revenue and follow-up continuity when that referral-out becomes routine.

Sources

1. 1Viscosupplementation for Management of Knee Osteoarthritis from an Indian Perspective: An Expert Consensus Report — National Institutes of Health, National Library of Medicine, Pain and Therapy, 2019
2. 2Injection-Based Management of Osteoarthritis of the Knee: A Systematic Review of Guidelines — National Institutes of Health, National Library of Medicine
3. 3Platelet-Rich Plasma for Knee Osteoarthritis: A Comprehensive Narrative Review — National Institutes of Health, National Library of Medicine, 2025
4. 4National Health Benefit Package 2.2 — National Health Authority, Ayushman Bharat PM-JAY
5. 5National Health Authority Revises Health Benefit Package of Ayushman Bharat PM-JAY — Press Information Bureau, Government of India

This article is for informational purposes and is not a substitute for professional medical advice. Injection choice for osteoarthritis is a clinical decision made between a patient and their treating orthopaedic specialist based on disease severity, joint condition and overall health; this article does not recommend a specific treatment for any individual case.